Resistance Costs and Future Drug Options of Antiretroviral Therapies: Analysis of the Role of NRTIs, NNRTIs, and PIs in a Large Clinical Cohort

REFERENCES

• Montaner JS, Reiss P, Cooper D, et al. A randomized, double blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV-infected patients: the INCAS Trial. Italy, the Netherlands, Canada and Australia Study. JAMA. 1998;279: 930–937.
   PubMed Web of Science ®Google Scholar
• Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efa-virenz plus zidovudine and lamivudine, efavirenz plus indi-navir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. New Engl J Med. 1999;341:1865–1873.
   PubMed Web of Science ®Google Scholar
• Squires KE, Gulick R, Tebas P, et al. A comparison of stavu-dine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START l). AIDS. 2000;14:1591–1600.
   PubMed Web of Science ®Google Scholar
• Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, em-tricitabine and efavirenz versus zidovudine, lamivudine and efavirenz for HIV. New Engl J Med. 2006;354:251–260.
   PubMed Web of Science ®Google Scholar
• Miller V, Larder BA. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleo-tide analogue drug exposure. Antiviral Ther 2001;6\(suppl 3):25–44.
   PubMed Web of Science ®Google Scholar
• Kuritzkes DR, Basset RL, Hazelwood D, Barret H, Rhodes RA, Young RK, Johnson VA, for the Adult ACTG 306 and 370 Teams. Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regi-mens. J Acquir Immune Defic Syndr 2004;36:600–603.
   Google Scholar
• Kuritzkes DR, Quinn JB, Benoit SL, et al. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS. 1996;10:975–981.
   PubMed Web of Science ®Google Scholar
• Maguire M, Gartland M, Moore S, et al. Absence of zid-ovudine resistance in antiretroviral-naive patients follow-ing zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANT! 2 and AVANT! 3 studies. AIDS. 2000;14:1195–1201.
   PubMed Web of Science ®Google Scholar
• Marcelin AG, Delaguerre C, Wirden M, Viegas P, Simon A, Katlama C, Calves V. Thymidine analogue reverse tran-scriptase inhibitors resistance mutations profiles and asso-ciation to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J Med Virol. 2004;72:162–165.
   Google Scholar
• Wainberg MA, Turner D. Resistance issues with new nu-cleoside/nucleotide backbone options. J Acquir Immune Defic Syndr 2004;37:536–43.
   Web of Science ®Google Scholar
• Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four drug regimens and pairs of sequential three drug regimens as initial therapy for HIV-1 infection. New Engl J Med. 2003;349:2304–2315.
   PubMed Web of Science ®Google Scholar
• Tebas P, Patric AK, Kane EM, Klebert MK, Simpson JH, Erice A, Powderly WG, Henry K. Virologic response to a ritonavir-saquinavir containing regimen in patients who had previously failed nelfinavir. AIDS. 1999;13:F23–28.
   PubMed Web of Science ®Google Scholar
• Katlama C, Schneider L, Agher R, Delaguerre C, Calvez V, Legrand M, Tubiana R. Ritonavir/amprenavir combination therapy in HIV infected patients who failed several prote-ase inhibitor containing regimens. AIDS. 2000;14\(suppl 4): S28.
   Google Scholar
• Jiang H, Deeks SG, Kuritzkes DR, Lallemant M, Katzen-stein D, Albrecht M, De Gruttola V. Assessing resistance costs of antiretroviral therapies via measures of future drug options. J Infect Dis. 2003;188:1001–1008.
   Google Scholar
• Bartlett JA, Buda JJ, von Scheele B, et al. Minimizing re-sistance consequences after virologic failure on initial com-bination therapy: a systematic overview. J Acquir Immune Defic Syndr 2006;41:323–331.
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Callegaro A, Airoldi M, Ravasio V, Ripamonti D, Gregis G, Suter F. Evaluation of 3 expert systems for genotypic analysis. In: Program and abstracts of the Eighth International Congress on Drug Therapy in HIV Infection; November 2006; Glasgow, UK. Abstract P213.
   Google Scholar
• Centers for Disease Control and Prevention. 1993 revised system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR. 1992;41:9–12.
   Google Scholar
• Lucas GN, Chaisson RE, Moore RD. Highly active antiret-roviral therapy in a large urban clinic: risk factors for viro-logic failure and adverse drug reactions. Ann Intern Med. 1999;131: 81–87.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Youle M, Moore A, et al. Reasons for modifica-tion and discontinuation of antiretrovirals: results from a single treatment centre. AIDS. 200115: 185–194.
   Google Scholar
• Department of Health and Human Services (DHHS). Guide-lines for the use of antiretroviral agents in HIV-infected adults and adolescents. November 10,2003. Available at: www.hivatis.org. Last accessed January 2006.
   Google Scholar
• De Luca A, Cingolani A, Di Giambenedetto S, et al. Variable prediction of antiviral treatment outcome by different sys-tems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J Infect Dis. 2003;187:1934–1943.
   PubMed Web of Science ®Google Scholar
• Kijak GH, Rubio AE, Pampuro SE, et al. Discrepant results in the interpretation of HIV-1 drug-resistance genotypic data among widely used algorithms. HIV Med. 2003;4:72–78.
   PubMedGoogle Scholar
• Sturmer M, Doerr HW, Staszewski S, Preiser W. Compari-son of nine resistance interpretation systems for HIV-1 ge-notyping. Antiviral Ther 2003;8:239–244.
   PubMed Web of Science ®Google Scholar
• Nelson M, Arasteh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. JAIDS. 2005;40:404–412.
   Google Scholar
• Youle M, Staszewski S, Clotet B, et al. Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations. HIV Clin Trials. 2006;7:86–96.
   PubMed Web of Science ®Google Scholar
• Montaner J, Guimaraes D, Chung J, Gaffor Z, Salgo M, DeMasi R. Prognostic staging of extensively pretreated patients with advanced HIV-1 disease. HIV Clin Trials. 2005;6:281–290.
   PubMed Web of Science ®Google Scholar
• Stanford University. Stanford HIV Drug Resistance Da-tabase. Available at: http://hivdb.stanford.edu. Last ac-cessed June 30,2006.
   Google Scholar
• Maggiolo F, Callegaro A, Ripamonti D, et al. Genotypic mutations in patients failing HAART with low level viremia. Presented at: 16th IAC; August 2006; Toronto, Canada. Ab-stract THPE0100.
   Google Scholar
• Ross L, Scarsella A, Raffanti S, et al. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV 1 isolated from zidovudine-naive patients experiencing vire-mia on stavudine containing regimens. AIDS Res Human Retro viruses. 2001;17:1107–1115.
   PubMed Web of Science ®Google Scholar
• Wainberg MA, Turner D. Resistance issues with new nu-cleoside/nucleotide backbone options. J Acquir Immune Defic Syndr 2004;37\(suppl 1):S36—S43.
   PubMed Web of Science ®Google Scholar
• Miller V, Larder BA. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue exposure. Antiviral Ther 2001 ;6\(suppl 3):25–44.
   PubMed Web of Science ®Google Scholar
• Lange J. A rationale approach to the selection and se-quencing of nucleoside/nucleotide analogues: a new para-digm. Antiviral Ther 2001;6\(suppl 3):45–54.
   PubMed Web of Science ®Google Scholar
• Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS. 2006;20: 711–718.
   PubMed Web of Science ®Google Scholar
• Klein MB, Willemot P, Murphy T, Lalonde RG. The impact of initial highly active antiretroviral therapy on future treatment sequences in HIV infection. AIDS. 2004;18:1895–1904.
   PubMed Web of Science ®Google Scholar